CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Research and Treatment. 2018;50(3):691-700. Published online 2017 July 6 DOI: https://doi.org/10.4143/crt.2017.280

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives

Marie Wislez, Etienne Giroux-Leprieur, Vincent Fallet, Jacques Cadranel

Lung Cancer: Targets and Therapy. 2016;83

Link1

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Yabing Cao, Guangli Xiao, Xibin Qiu, Sheng Ye, Tongyu Lin

PLoS ONE. 2014;9(12):e114008

Link1

Estimating the Budget Impact of Crizotinib for Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Argentina

B. Wang, W. Furnback, J. Xuan

Value in Health. 2014;17(3):A74

Link1 Link2

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer

Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok

Cancer Research and Treatment. 2018;50(3):691-700

Link1

Link2 Link3

Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung Cancer

Nobuhiro Asai, Etsuro Yamaguchi, Akihito Kubo

Clinical Lung Cancer. 2014;15(3):e33-e35

Link1 Link2

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib

Evelyn M. Brosnan, Andrew J. Weickhardt, Xian Lu, Delee A. Maxon, Anna E. Barón, Michel Chonchol, D. Ross Camidge

Cancer. 2013;120(5):664-674

Link1

Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma

Quan Zhang, Na Qin, Jinghui Wang, Jialin Lv, Xinjie Yang, Xi Li, Jingying Nong, Hui Zhang, Xinyong Zhang, Yuhua Wu, Shucai Zhang

Thoracic Cancer. 2015;7(1):3-8

Link1

Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer

Brian Won, Isa Mambetsariev, Ravi Salgia

BMC Cancer. 2016;16(1):

Link1

Link2 Link3 Link4

174P: Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)

K. Wilner, T. Usari, A. Polli, E. Kim

Journal of Thoracic Oncology. 2016;11(4):S133

Link1 Link2

Cost-Effectiveness of Eml4-Alk Gene Targeted First-Line Ceritinib Treatment Among Patients With Advanced Alk-Positive Non–Small Cell Lung Cancer

N. Upadhyay, N. Atreja

Value in Health. 2015;18(3):A203

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.